PRINCETON, New JerseyCytogen Corporation’s ProstaScint (capromab
pendetide) is being evaluated in a phase I/II clinical study for its utility in
helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
ProstaScint is a radiolabeled monoclonal antibody that targets prostate specific
membrane antigen. In the study, the specific areas of greatest tumor burden
within the prostate, identified by the ProstaScint image, will receive boosted
doses of radiation via IMRT.